Assessment Group (ScHARR) Comments on the ACD for Follicular lymphoma - rituximab (review of TA110)

The Assessment Group had two minor comments on the ACD for the above multiple technology appraisal:

1) p.10: Section 4.1.10: Although an increased statistically significant incidence of leukocytopenia, neutropenia and granulocytopenia was observed in the trials in the rituximab plus chemotherapy arms, this was not associated with an increase in the rate of infection (infection is associated with leukocytopenia, neutropenia and granulocytopenia).

This is incorrect. Most trials did not report if leucocytopenia, neutropenia and granulocytopenia were of a statistically significant difference between R-chemo and chemo arms. The exceptions were:

- A statistically significant difference in granulocytopenia between the R-CHOP and CHOP arms in the GLSG-2000 trial
- A Statistically significant difference in neutropenia for the FL2000 trial.
- Leukocytopenia was not significantly different between R/CHOP and CHOP in the GLSG-2000 trial.

2) **p 12: Section 4.2.2: Three of the trials (Dunbar et al, 2006, 2009 and Homberger) only considered rituximab plus CVP**

This is incorrect. These are not trials but economic evaluations. Furthermore, the names should be corrected from *Dunbar* to *Dundar* and *Homberger* to *Hornberger*.